Submit your abstract via the Japanese Website
if your study includes Japanese research participants.
Noon, Wednesday, December 19, 2018 -
Noon, Wednesday, February 27, 2019
(Japan Standard Time)
JSMO2019 accepts abstracts for free paper.
Presentation style will be either Oral or Poster presentation.
Please select the abstract category from the list below. (The 1st & 2nd choices are required.)
|01. Gastrointestinal Cancer||
01-01. Esophageal Cancer
01-02. Gastric Cancer
01-03. Small Bowel Cancer
01-04. Colorectal Cancer
01-05. Other (Appendix Cancer, Anal Cancer, etc.)
02. Hepatobiliary/Pancreatic Cancer
02-01. Liver Cancer
02-02. Gallbladder and Biliary Tract Cancer
02-03. Pancreatic Cancer
03. Lung Cancer/Thoracic Cancer
03-01. Early Stage Non-Small Cell Lung Cancer/Perioperative Treatment
03-02. Locally Advanced Non-Small Cell Lung Cancer
03-03. Metastatic Non-Small Cell Lung Cancer/Chemotherapy
03-04. Metastatic Non-Small Cell Lung Cancer/Tyrosine Kinase Inhibitor
03-05. Metastatic Non-Small Cell Lung Cancer/Immunotherapy
03-06. Small Cell Lung Cancer
03-07. Other (Mesothelioma, Thymic Malignancies, etc.)
04. Hematologic Malignancies
04-03. Other (Myeloma etc.)
|05. Breast Cancer||
05-01. Early Breast Cancer/Perioperative Therapy
05-02. Metastatic Breast Cancer
|06. Gynecologic Cancer||06-01. Gynecologic Cancer|
|07. Genitourinary Cancer||07-01. Genitourinary Cancer|
|08. Head and Neck Cancer||08-01. Head and Neck Cancer|
09. Rare Cancer/Cancer of Unknown Primary
09-01. Pediatric Oncology
09-02. Central Nervous System Tumors
09-03. Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor
09-04. Skin Cancer
09-06. Germ Cell Tumor
09-07. Cancer of Unknown Primary
10. Translational Research/Clinical Pharmacology
10-01. Basic Research
10-02. Clinical Pharmacology
10-03. Innovative Drug Research & Development
10-04. Molecular Diagnostics/Genetic Testing
10-05. Translational Research
10-06. Companion Diagnostics
10-07. Developmental Therapeutics
11. Palliative Care/Symptom Management
11-01. Palliative Medicine
11-02. Symptom Management
11-03. Oral Care for Cancer Patients
|12. Cross-sectional Program||
12-01. Radiation Oncology
12-02. Diagnostic Imaging
12-03. Familial and Hereditary Cancer
12-05. Cancer Prevention
12-06. Immunobiology and Immunotherapy
13. Multidisciplinary Team Program
13-01. Interdisciplinary Approach to Cancer Care
13-03. Outpatient Chemotherapy
13-04. Professional Oncology Education
13-05. Oncology Nursing
14. Clinical Trial Facilitation Program
14-02. Clinical Trial Support
14-03. Trials in Progress
14-04. Research Ethics
14-05. Health Policy/Regulatory Affairs/Reimbursement
14-06. Health Technology Assessment/Health Economics
15. Patient Advocacy/Survivorship
15-01. Patient Advocacy
15-03. Geriatric Oncology
15-04. Community Cancer Care
15-05. Adolescents and Young Adults with Cancer
|16. Miscellaneous||16-01. Miscellaneous|
(a) Please note that if you select "Trials in Progress," your abstract will NOT be included in electronic program. Your submitted abstracts will be printed and handed out to the participants at the room where you deliver your presentation.
* Abstract Young Investigator Award
* All submitted abstracts will be reviewed by the Peer Review Committee and decided comprehensively based on the study contents, ethical aspects, and etc. You may choose the presentation style (oral or poster) when you submit an abstract. However, please understand that the congress president will make a final decision on the presentation style, presentation session, as well as acceptance/rejection.
JSMO2019 would like to deepen discussions based on the latest research results. We accept such abstracts as "Late-breaking abstracts".
If you are applying for Late-breaking abstracts, please select "Yes" for the question, "Are you applying for late-breaking abstracts?" and submit an outline and predicted results of your research as interim registration in the abstract text box.
Please complete the abstract submission with the latest research results by Friday, June 14, 2019. (You will be notified by the Secretariat to complete the abstract submission at the beginning of April.)
* The accepted results are not influenced even if the actual research results were different from your prediction.
JSMO2019 will select the abstracts for "Presidential Sessions" from the submitted abstracts this year instead of usual Plenary Session. The selection flow is as follows.
The program committee members choose the following number of abstracts from each category.
38 abstracts in total: 6 abstracts from each Gastrointestinal Cancer and Lung Cancer/Thoracic Cancer, and each 2 abstracts from other category.
Congress president selects 12 abstracts out of 38 abstracts, and the final selection will be made at the program committee.
There is one session a day, and each session is 120 minutes consisting of 4 presentations.
Each presentation is 30 minutes in total (presentation 15 min, Q&A 5 min and discussion 10 min).
Abstracts submitted by young researchers from outside Japan will be reviewed by the JSMO2019 committee members. Those selected presenters will be awarded partial travel grant for their outstanding works. Abstracts authors are encouraged to apply for Travel Award as outlined below:
Note: To qualify for the travel award, you must be free of any commercial grant or support.
Noon, Wednesday, December 19, 2018 - Noon, Wednesday, February 27, 2019, Japan Standard Time (same as the application period for JSMO2019 abstracts)
Young overseas doctors/researchers, who live outside of Japan, 40 years old or younger, as of July 20, 2019 (the last day of JSMO2019).
Please apply by submitting your abstract from the Submission Page (click the "Submit" button below).
Each applicant will be notified by e-mail around the beginning of May, 2019.
Those selected presenters will get a chance of having on-site tour to visit institutions and private enterprises in Kyoto as an award.
Abstracts (oral/ poster) submitted in English for JSMO2019 Annual Meeting will be published in ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Oxford University Press).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".
However, in case that there is any possibility of duplicate publication or encore publication, please refrain from selecting "Yes".
* Terms to be published in Journal "Annals of Oncology" as to poster presentation:
Oral presentations are free of charge but poster presentations are required 5000JPY of the posting fee of "Annals of Oncology" in addition to the Congress registration fee.
You can cancel publication of the journal after the acceptance notice.
We will contact you to confirm your final intention when the presentation style is decided.
The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2016 - December 31, 2018.
COI Policy (in revision)
Detailed Enforcement regulations of COI (in revision)
For oral presentation, please use the slide below as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.
|(1)||If your study for this presentation is supported by research funds|
|(2)||If you are or have been an employee of a company and/or a profit-making organization related to medicine|
|(3)||If you have earned ＞￥1,000,000/year as an officer or advisor of a company and/or a profit-making organization related to medicine|
|(4)||If you hold＞5％ of the stock of a company and/or a profit-making organization related to medicine, or receive dividends ＞￥1,000,000/year|
|(5)||If you have earned ＞￥1,000,000/year as a patent fee from a company and/or a profit-making organization related to medicine|
|(6)||If you have earned ＞￥500,000/year as a lecture fee from a company and/or a profit-making organization related to medicine|
|(7)||If you have earned ＞￥500,000/year as a manuscript fee from a company and/or a profit-making organization related to medicine|
|(8)||If you have research expenses ＞￥1,000,000/year from a company and/or a profit-making organization related to medicine|
|(9)||If you have received ＞￥1,000,000/year as a certain contribution from a company and/or a profit-making organization related to medicine|
|(10)||If you are or have been involved in a certain endowed chair funded by a company and/or a profit-making organization related to medicine|
|(11)||If you have ＞￥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company and/or a profit-making organization related to medicine|
|(12)||If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research）equivalent to ＞￥50,000/year from a company and/or a profit-making organization related to medicine|
|(13)||If you are a representative of an organization for clinical study which receives research expenses（donation, contract, others）from a company and/or a profit-making organization related to medicine|
Questions regarding COI disclosure
The Secretariat of the Japanese Society of Medical Oncology
In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO ask you to declare the following items:
The content of your declaration will not affect the acceptance or rejection of your abstract.
Please submit to the following:
We accept abstracts submitted online only through the submission system.
You may enter the submission page from "Abstract Submission" button at the bottom of this page.
* It is recommended that you prepare your abstract text by Word/ text file in advance, and then copy it on the registration page.
* After completing the abstract submission, the abstract registration ID number and your password will be sent to the first author’s email address. The ID number and password will be required to confirm/modify/delete/add abstracts. Please be sure to enter the correct e-mail address. Please be sure to keep the ID number and password by yourself. The congress secretariat will NOT keep track of your information.
You can access to confirm/modify/delete/add abstracts during the abstract submission period.
The ID number and password will be required to enter the page (confirm/modify/delete/add abstracts).
Notification of acceptance/rejection will be sent to the first author by email by May, 2019.
c/o Congress Corporation
5-1 Koji-machi, Chiyoda-ku, Tokyo, Japan
Phone: +81-3-5216-5318 Fax: +81-3-5216-5552